Deciphera Pharmaceuticals has been granted a patent for low impurity compositions containing a specific compound for treating disorders related to c-KIT and PDGFRa kinases. The patent claims a pharmaceutical composition for oral delivery of the compound. GlobalData’s report on Deciphera Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Deciphera Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Deciphera Pharmaceuticals's grant share as of January 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11850240B1) discloses pharmaceutical compositions designed for the oral delivery of a compound represented by Formula (I). The compositions described in the patent consist of a solid dispersion containing an amorphous form of the compound. This innovative approach aims to enhance the bioavailability and efficacy of the compound when administered orally.
Furthermore, the patent claims also include the incorporation of one or more pharmaceutically acceptable carriers along with the solid dispersion in the pharmaceutical composition. This combination is intended to improve the stability and overall performance of the oral delivery system. By utilizing an amorphous form of the compound represented by Formula (I) in the solid dispersion, the composition seeks to overcome challenges related to poor solubility and absorption, ultimately leading to more effective oral delivery of the compound.
To know more about GlobalData’s detailed insights on Deciphera Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.